Multiple TKIs that target RET have shown minimal therapeutic benefit in patients with RET rearrangements in their malignancies, includes cabozatinib [89] (tumor response rate of 28% and median PFS of 5.5 months) and vendatinib [90] (response rate of 18% and median PFS of 4.5 months). This evidence concerns the gene RET and neoplasm.